KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other financing activities (2016 - 2025)

Historic Other financing activities for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Q3 2025 value amounting to $1.1 million.

  • Vertex Pharmaceuticals' Other financing activities rose 2222.22% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 789.47%. This contributed to the annual value of $6.2 million for FY2024, which is 24444.44% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Other financing activities stood at $1.1 million for Q3 2025, which was up 2222.22% from $700000.0 recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other financing activities peaked at $3.5 million during Q1 2024, and registered a low of -$1.5 million during Q4 2023.
  • Its 5-year average for Other financing activities is $1.0 million, with a median of $1.1 million in 2022.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 173908.05% in 2021, then crashed by 23636.36% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Other financing activities (Quarter) stood at $1.4 million in 2021, then dropped by 21.43% to $1.1 million in 2022, then tumbled by 236.36% to -$1.5 million in 2023, then surged by 160.0% to $900000.0 in 2024, then rose by 22.22% to $1.1 million in 2025.
  • Its Other financing activities was $1.1 million in Q3 2025, compared to $700000.0 in Q2 2025 and $800000.0 in Q1 2025.